Tags

Type your tag names separated by a space and hit enter

Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
Eur J Cancer Prev. 2006 Jun; 15(3):225-32.EJ

Abstract

BACKGROUND

The scientific debate on the role of dietary phytoestrogens for prevention of breast cancer is still ongoing. We previously reported an inverse association between dietary phytoestrogen intake and premenopausal breast cancer risk and now examine the relationship with plasma phytoestrogen concentrations.

METHODS

We measured enterolactone (mammalian lignan) and genistein (isoflavone) concentrations in plasma samples of 220 premenopausal cases and 237 age-matched controls from a population-based case-control study in Germany.

RESULTS

Median plasma enterolactone concentrations in cases and controls were 6.3 and 9.7 nmol/l, respectively, and median genistein concentrations were 4.5 and 3.7 nmol/l, respectively. Premenopausal breast cancer risk decreased with increasing plasma enterolactone concentrations. Adjusted odds ratios (95% confidence intervals) were 0.42 (0.20-0.90) and 0.38 (0.17-0.85) (P for trend 0.007) for women in the third and fourth quartile of plasma enterolactone compared to those in the lowest quartile. There was no significant association between plasma genistein concentration and premenopausal breast cancer risk.

CONCLUSION

Using biomarkers of phytoestrogen intake, we confirmed the strong inverse association between enterolactone and premenopausal breast cancer risk as found with dietary intake estimates. This result gives support to the potential role of mammalian lignans for breast cancer prevention among premenopausal women in Western populations.

Authors+Show Affiliations

Unit of Human Nutrition and Cancer Prevention, Technical University of Munich, and German Cancer Research Center, Department of Clinical Epidemiology, Heidelberg, Germany.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16679865

Citation

Piller, Regina, et al. "Plasma Enterolactone and Genistein and the Risk of Premenopausal Breast Cancer." European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), vol. 15, no. 3, 2006, pp. 225-32.
Piller R, Chang-Claude J, Linseisen J. Plasma enterolactone and genistein and the risk of premenopausal breast cancer. Eur J Cancer Prev. 2006;15(3):225-32.
Piller, R., Chang-Claude, J., & Linseisen, J. (2006). Plasma enterolactone and genistein and the risk of premenopausal breast cancer. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP), 15(3), 225-32.
Piller R, Chang-Claude J, Linseisen J. Plasma Enterolactone and Genistein and the Risk of Premenopausal Breast Cancer. Eur J Cancer Prev. 2006;15(3):225-32. PubMed PMID: 16679865.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasma enterolactone and genistein and the risk of premenopausal breast cancer. AU - Piller,Regina, AU - Chang-Claude,Jenny, AU - Linseisen,Jakob, PY - 2006/5/9/pubmed PY - 2006/12/9/medline PY - 2006/5/9/entrez SP - 225 EP - 32 JF - European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) JO - Eur. J. Cancer Prev. VL - 15 IS - 3 N2 - BACKGROUND: The scientific debate on the role of dietary phytoestrogens for prevention of breast cancer is still ongoing. We previously reported an inverse association between dietary phytoestrogen intake and premenopausal breast cancer risk and now examine the relationship with plasma phytoestrogen concentrations. METHODS: We measured enterolactone (mammalian lignan) and genistein (isoflavone) concentrations in plasma samples of 220 premenopausal cases and 237 age-matched controls from a population-based case-control study in Germany. RESULTS: Median plasma enterolactone concentrations in cases and controls were 6.3 and 9.7 nmol/l, respectively, and median genistein concentrations were 4.5 and 3.7 nmol/l, respectively. Premenopausal breast cancer risk decreased with increasing plasma enterolactone concentrations. Adjusted odds ratios (95% confidence intervals) were 0.42 (0.20-0.90) and 0.38 (0.17-0.85) (P for trend 0.007) for women in the third and fourth quartile of plasma enterolactone compared to those in the lowest quartile. There was no significant association between plasma genistein concentration and premenopausal breast cancer risk. CONCLUSION: Using biomarkers of phytoestrogen intake, we confirmed the strong inverse association between enterolactone and premenopausal breast cancer risk as found with dietary intake estimates. This result gives support to the potential role of mammalian lignans for breast cancer prevention among premenopausal women in Western populations. SN - 0959-8278 UR - https://www.unboundmedicine.com/medline/citation/16679865/Plasma_enterolactone_and_genistein_and_the_risk_of_premenopausal_breast_cancer_ L2 - http://dx.doi.org/10.1097/01.cej.0000197449.56862.75 DB - PRIME DP - Unbound Medicine ER -